Hybridon is developing immunomodulatory oligonucleotides. including injectable HYB-2055 (IMOxine) which acts as an agonist of toll-like receptor 9, for the potential treatment of cancer. HYB-2055 is currently undergoing phase II clinical trials. The immunomodulatory oligonucleotides are also being investigated for the potential treatment of infectious diseases and immune disorders.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
immunomodulatory oligonucleotides
8
potential treatment
8
technology evaluation
4
evaluation hyb-2055
4
hyb-2055 hybridon
4
hybridon hybridon
4
hybridon developing
4
developing immunomodulatory
4
oligonucleotides including
4
including injectable
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!